A humanized anti-NGF antibody or a fragment thereof which maintains binding activity to NGF, wherein the humanized anti-NGF antibody comprises, (a) a VH region having a first CDR comprising the amino acid sequence GFSLTNNNVNW, a second CDR comprising the amino acid sequence GVWAGGATDYNSALKS, and a third CDR comprising the amino acid sequence DGGYSSSTLYAMDA； and (b) a VL region having a first CDR comrising the amino acid sequence RASEDIYNALA, a second CDR comprising the amino acid sequence HT, and a third CDR sequence comprising the amino acid sequence QHYFHYPRT.
